DSIP: Side Effects & Safety

DSIP has a generally favorable safety profile in published research, with no significant toxicity reported at standard research doses. The peptide is based on an endogenous neuropeptide, though the synthetic form is administered at doses higher than natural physiological levels.

• Drowsiness: When used for sleep, some residual sedation may be experienced — though this is typically milder than with conventional sleep medications
• Injection site reactions: Standard subcutaneous injection effects
• Headache: Occasionally reported, typically mild
• Vivid dreams: Altered dream activity reported by some users, consistent with changes in sleep architecture
• Mood changes: Mild mood effects (both positive and occasionally negative) reported in some studies

• Published research is relatively old (primarily 1980s–1990s) — modern clinical trials with current standards are lacking
• Tolerance may develop with extended daily use, reducing effectiveness
• Interactions with endocrine function (cortisol, GH, LH) mean caution is needed with concurrent hormonal treatments
• Not studied in pregnant or breastfeeding individuals

• Concurrent use of other sedative or sleep-promoting substances
• Endocrine disorders (due to DSIP's effects on multiple hormonal axes)
• Pregnancy and breastfeeding

Return to the DSIP overview for general information.